Acute myeloid leukemia (AML) cells exposed to genotoxic agents arrest their cell cycle at the G2/M checkpoint and are inherently chemoresistant. To understand the mechanism of this chemoresistance, we compared the ability of immature CD34 þ versus mature CD34À AML cell lines (KG1a and U937, respectively) to recover from a DNA damage-induced cell cycle checkpoint in G2. Here, we report that KG1a cells have a more stringent G2/M checkpoint response than U937 cells. We show that in both cell types, the CDC25B phosphatase participates in the G2/M checkpoint recovery and that its expression is upregulated. Furthermore, we show that CHK1 inhibition by UCN-01 in immature KG1a cells allows checkpoint exit and induces sensitivity to genotoxic agents. Similarly, UCN-01 treatment potentializes genotoxic-induced inhibition of colony formation efficiency of primary leukemic cells from AML patients. Altogether, our results demonstrate that checkpoint stringency varies during the maturation process and indicate that targeting checkpoint mechanisms might represent an attractive therapeutic opportunity for chemoresistant immature AML cells.
Introduction
Acute myeloid leukemia (AML) is a common acute leukemia in adults and its prognosis remains poor. Even though AML patients enter into complete remission using standard protocols, 70-80% of them relapse and become resistant to chemotherapy. This resistance is thought to be related to the intrinsic chemoresistance of leukemia stem cells (Blagosklonny, 2006) .
It has been reported that DNA-damaging agents such as ionizing radiation or drugs may trigger different responses depending on AML cell differentiation. For example, after ionizing radiation exposure, HL-60 or U937 cells (mature CD34À AML cells) undergo apoptosis whereas KG1a, KG1 or TF1 (immature CD34 þ AML cells) display an intense and prolonged G2/M block followed by growth recovery or mitotic catastrophe, depending on the dose of ionizing radiation (Clave et al., 1997; Bruno et al., 1998) . In AML cell lines with an immature phenotype, DNA damage results in a G2/M cell cycle block rather than interphasic cell death. Similar findings have been described with other DNA-damaging agents such as calicheamycin (Amico et al., 2003) . These data suggest that immature AML cells (and therefore perhaps leukemia stem cells) preferentially use the G2/M block and it is possible that prolonged arrest before mitosis could therefore offer a significant survival advantage following genotoxic stress during consolidation treatment.
The G2/M checkpoint is a barrier to aberrant cellular proliferation, which either arrests damaged cells to allow time for repair or initiates programmed cell death when damage is irreparable (Nyberg et al., 2002; Xu et al., 2002) . In recent years, the mechanism of G2/M arrest after DNA damage has been partially elucidated. When DNA is injured by genotoxic agents, the checkpoint kinases (CHK1 and CHK2), which function in an ATM/ATR-dependent manner, are activated (Bartek and Lukas, 2003; Shiloh, 2003) . ATR phosphorylates and activates its effector kinase CHK1 in a process that critically depends on claspin (Kumagai and Dunphy, 2000; Chini and Chen, 2003) . Phosphorylated claspin interacts with the kinase domain of CHK1, thus promoting phosphorylation by ATR and the enhancement of CHK1 autophosphorylation (Clarke and Clarke, 2005; .
The checkpoint kinases then inactivate CDC25 phosphatases by phosphorylation that trigger their relocalization and/or degradation. In turn, the activities of the CDK1-cyclin complexes that are required to control entry into mitosis are kept inactive. There are three CDC25 phosphatases in human (CDC25A, B and C) and their inactivation appears to be essential for cell cycle arrest (see for review). Cdk1 is also kept inactive via inhibitory phosphorylation by the WEE1 kinase (Smits and Medema, 2001) .
Once DNA damage is repaired, the DNA-damage checkpoint is silenced so that cell cycle progression is allowed to resume. It has been shown that CDC25B is essential in the recovery of the cell after DNA-damage checkpoint-induced arrest Bugler et al., 2006) . Similarly, the PLK1 kinase is also required in this pathway, probably by participating in the control of the proteasomal degradation of the WEE1 inhibitory kinase (Watanabe et al., 2005) and claspin (Mamely et al., 2006) , a process that depends on the SCFbTrCP ubiquitin ligase (Mailand et al., 2006; Peschiaroli et al., 2006) .
Checkpoint pathways activated in response to DNA damage appear to be central to the response of cells to chemotherapeutic agents and in the ability of tumor cells to develop chemoresistance. In this study, we investigated this issue in AML cells. We have examined the expression and function of CDC25B, CHK1, PLK1, WEE1 and claspin in regulating the checkpoint induced by a DNA-damaging agent. We demonstrate that UCN-01 can abrogate the G2 checkpoint and increase both the cytotoxicity of DNA-damaging agents and apoptosis, in AML cell lines and in primary leukemia cells.
Results
KG1a cells display a more stringent control of the G2/M checkpoint than U937 cells We compared the abilities of immature CD34 þ (KG1a) and mature CD34À (U937) AML cell lines to enter into mitosis upon activation of a DNA damage-dependent G2/M checkpoint. To monitor entry into mitosis, we analyzed cell cycle progression using a protocol based on the previously described 'mitotic trap' assay (Roberge et al., 1998) . As schematically depicted in Figure 1a , cells were treated with etoposide (VP-16) for 1 h then released in VP-16 free media for an additional 23 h to allow DNA-damage checkpoint activation and cell cycle arrest in late G2-phase. In addition, nocodazole was added to the media, thus trapping the cells that could overcome or exit the G2/M checkpoint in a mitosis-like state. Flow cytometry and phospho-histone H3 antibodies were used to monitor cells entering into mitosis and the presence of DNA damage was detected by gH2AX antibodies. As shown in Figure 1b , in the absence of activation of the G2/M checkpoint by VP-16, most of the U937 and KG1a cells proceeded into mitosis where they were blocked by nocodazole treatment. When the cells were treated with VP-16, DNA damage induced a cell cycle arrest at the G2/M checkpoint and subsequent entry into mitosis was found to depend upon the concentration of VP-16. However, we found substantial differences in the percentage of mitotic cells (Roberge et al., 1998) . (b, c) U937 and KG1a cells were treated with increasing concentrations of VP-16 for 1 h then released in drug free media in the presence of nocodazole (50 or 100 ng ml
À1
, respectively) for an additional 23 h. Flow cytometry was used to monitor mitosis using phospho-histone H3/Alexa488 antibodies and the presence of DNA damage with gH2AX/Alexa568 antibodies. The results presented here are representative of three independent experiments. (Humbert et al., 2002) . In the same experiment, we also examined the G2/M checkpoint recovery efficiency by monitoring histone-gH2AX labeling in mitotic cells, as it has been shown that the level of its expression correlates with the amount of double-strand breaks (DSBs) in the DNA (McManus and Hendzel, 2005; Bouquet et al., 2006) . As shown in Figure 1c , a significant percentage of U937 cells exposed to VP-16 accumulated in mitosis in the presence of DNA damage that probably resulted from an early exit of the G2/M checkpoint (2 and 4.8% for 1 and 10 mM VP-16, respectively). In contrast, KG1a cells that entered mitosis did not show any evidence of DNA damage detectable with histone gH2AX labeling. These results indicate that the mature U937 cell line has the capacity to resume the G2/M checkpoint, a feature that might contribute to its higher sensitivity to genotoxic agents. In contrast, immature KG1a cells display a more stringent G2/M checkpoint response, thereby controlling illegitimate entry into mitosis in the presence of unrepaired DNA damage, a feature that probably largely participates in their resistance to genotoxic agents.
CDC25B plays a role in G2/M checkpoint recovery
In an attempt to further investigate the mechanism by which leukemia cell lines are able to recover from the DNA-damage cell cycle checkpoint in G2, we performed similar experiments to that described in Figure 1a in the presence of the BN82685 compound, a previously described selective chemical inhibitor of CDC25 phosphatases (Brezak et al., 2005) . We found that treatment with VP-16 and BN82685 led to a significant decrease in the percentage of mitotic cells over time in the U937 and KG1a cultures and that this occurred in a BN82685 dose-dependent manner (Figures 2a and b) , indicating that mitotic entry was impaired following the inhibition of all CDC25 phosphatases. To test the specific role of the CDC25B phosphatase in checkpoint recovery, we inhibited its expression with small interfering RNA (siRNA) in mature U937 cells treated with VP-16. As shown in Figure 2c (insert), transfection with siRNA against CDC25B largely reduced its protein level. To examine the consequence of this partial inhibition on checkpoint recovery, siRNA transfected cells were treated with VP-16 (2 mM) for 1 h then incubated in fresh medium containing nocodazole for 23 h. Entry into mitosis was monitored in the population of siRNA transfected cells that were identified by green fluorescent protein expression in cotransfected cells. We found that CDC25B inhibition resulted in a partial but statistically significant inhibition of checkpoint recovery and entry into mitosis in comparison to cells treated with a control siRNA ( Figure 2c ).
These data therefore confirm that CDC25B plays a role in the control of entry into mitosis after a DNA damage-activated checkpoint in AML cell lines. Figure S1) , and correspond to the IC25 for both cell lines (IC50 of 12 and 138 mM for U937 and KG1a, respectively). On the basis of these results, a time course monitoring of CDC25B expression by western blot together with cell cycle distribution analyses were performed in U937 and KG1a cells exposed to VP-16, 5 and 70 mM, respectively (Figures 3a and b) . U937 cells retained modest CDC25B expression levels immediately after VP-16 treatment (post-treatment), with the detection of lower electrophoretic mobility forms of CDC25B, which decreased until 10 h post-treatment. Strikingly, an 
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C Didier et al increase in the level of CDC25B was observed after 24 h, concomitant with a progressive exit of the cells from the G2/M checkpoint as shown by flow cytometry analysis ( Figure 3a) . Similar results were observed in additional experiments with VP-16 concentration up to 10 mM (data not shown). Similar experiments performed on KG1a cells revealed that the CDC25B protein levels also progressively decreased after treatment, then recovered to a high level at 36 and 48 h post-treatment. However, in these cells, analyses of the DNA content showed an intense and prolonged cell cycle arrest with a G2 DNA content, but in the absence of significant cell death, as shown by lack of cells with sub-G1 DNA content (Figure 3b) . A similar accumulation of CDC25B was observed when the experiment was performed in the presence of VP-16 concentrations ranging from 20 to 200 mM (data not shown).
These observations indicate that a strong increase in the level of CDC25B is observed in U937 and KG1a after DNA damage. However, only in U937 cells is this increase associated with an ability to exit the G2/M checkpoint. KG1a cells remain predominantly arrested at the checkpoint and entry into mitosis is very limited. Thus, from these experiments we can conclude that in KG1a cells, the weak increase in CDC25B levels after DNA damage does not seem to be sufficient to allow checkpoint recovery.
To gain more insight into the molecular mechanisms of the G2 checkpoint recovery, we monitored CHK1 and pSer317-CHK1 expression level by western blot analyses in U937 and KG1a cells exposed to VP-16 (Figure 3c ). No significant change in total CHK1 protein levels could be observed. However, in both cell lines, a striking CHK1 activation was detected by phosphorylation on S317 in response to genotoxic stress. Interestingly, CHK1 phosphorylation appears to decrease more rapidly in U937 than in KG1a. We also examined PLK1 level and observed a minor increase 24 h after VP-16 treatment in U937 cells, concomitant with a progressive exit of the cells from the G2/M checkpoint (Figure 3c ). The PLK1 level was also found to be significantly increased in KG1a cells, but this was not correlated with exit from the G2 block.
We therefore addressed the question of PLK1 activity by monitoring the levels of claspin and WEE1. As shown in Figure 3c , claspin level initially increased in U937 cells exposed to VP-16, then decreased at 24 and 48 h after treatment. By contrast, in KG1a cells, claspin protein level rapidly increased and remained elevated in response to VP-16. WEE1 protein level was found to decrease at late time point in response to genotoxic treatment in both cells lines.
Taken together, these observations are in favor of a more intense and prolonged checkpoint activation in the KG1a cell line than in U937 cells.
Combined exposure of KG1a immature AML cells to VP-16 and UCN-01 results in dramatic checkpoint recovery We next sought to overcome the G2/M checkpoint mechanism in the KG1a cells using the CHK1 kinase inhibitor UCN-01 (Graves et al., 2000) . Recovery from the G2/M checkpoint was examined by monitoring the percentage of mitotic cells (Figure 4a ) and by the progressive entry into an apoptotic process ( Figure 4b ). As shown, treatment of KG1a cells with 100 nM UCN-01 alone already had a mitotic and proapoptotic inducing effect, suggesting that CHK1 indeed exerts a strong inhibitory effect on cell cycle progression. Combination of UCN-01 with VP-16 treatment resulted in a more significant increase in the percentage of mitotic and apoptotic cells (Figures 4a and b) .
To assess the specific role of CHK1, KG1a cells were transfected with CHK1 siRNA, leading to an important decrease in CHK1 protein level (Figure 4c) . A significant increase in mitotic population of cells transfected with CHK1 siRNA was observed following VP-16 (10 mM) exposure (Po0.001). Taken together, these findings indicate that CHK1 siRNA abolishes the strong G2 checkpoint and sensitizes the immature KG1a cells to a DNA-damaging agent.
Checkpoint recovery in AML blasts from patients
To examine the role of CHK1 in resistance of AML blasts from patients, we evaluated whether the effect of UCN-01 could sensitize the colony formation efficiency of primary leukemic cells from patient samples to treatment with VP-16. The colony formation efficiency of AML blasts treated with VP-16 and/or UCN-01, was monitored and the IC50 for VP-16 was determined (Figure 5a ). We found that combination with UCN-01 had a strong potentialization effect with an important decrease of the IC50 for VP-16. The sensitization factor, which is the ratio between the IC50 for VP-16 alone and VP-16 in combination with UCN-01, was derived from these data.
Based on these findings, we compared the sensitization factors from 17 AML patients belonging to the M1 and M2 classes with those of AML patients belonging to the M4 and M5 classes of the French-American-British classification. As shown in Figure 5b , combination of VP-16 with UCN-01 had a significant potentializing effect on M1 and M2 (mean 2.1±0.4) compared to M4 and M5 groups (mean 1.0 ± 0.1) (Po0.05, Figure 5b ). To elucidate the mechanism(s) by which M1 and M2 patients are more readily sensitized to UCN-01, we evaluated in six patients from each group the total CHK1 level and the phosphorylation of Ser345, an indicator of its activation level. For this purpose, AML blasts from patients were grown in EGM2 medium in the presence of SCF, GM-CSF, IL-3 and Flt3 ligand for 48 h before analyses. Cell cycle distribution was monitored and no significant difference was observed between the two groups (Supplementary Figure S2) . As shown in Figure 5c , we observed variability in CHK1 expression and activation level in the two AML patient groups. However, these results could not be correlated with sensibilization status.
In conclusion, these results indicate that in both KG1a immature cells and leukemic progenitors cells from AML patients, G2/M checkpoint recovery and enhanced cytotoxicity in response to genotoxic agents is observed when the inhibition of CDC25B phosphatase by CHK1 is prevented by UCN-01 treatment.
Discussion
It is generally believed that the inherent resistance of cells to DNA-damaging agents is primarily due to their ability to repair DNA damage (Warters et al., 1995; Bao et al., 2006) . However, increasing evidence also suggest that the ability of a tumor cell that has been exposed to DNA injury to exit from cell cycle arrest and enter mitosis or on the contrary, to avoid illegitimate recovery in the presence of persisting lesions, is central to its sensitivity to genotoxic agents.
Acute Myeloid Leukemia cells are naturally resistant to chemotherapeutics currently used in the clinic and a highly significant proportion of patients relapse. Hence, resistance of AML cells to chemotherapy has been proposed to be associated with reinforcement of a DNA damage-activated checkpoint (Clave et al., 1997; Bruno et al., 1998) . In the study reported here, we have investigated this issue at the molecular level in AML cell lines and in leukemic progenitor cells from AML patients.
In the first place, exit from a G2/M cell cycle arrest was examined in mature and immature leukemia cells following exposure to genotoxic agents. We demonstrate that the response of leukemia cells to genotoxic stress differs, depending on the cell type. Immature KG1a cells were found to tightly control their DNA-damage checkpoint, which can account for their relative chemoresistance. In contrast, we have shown that U937 mature cells are prone to exit from the G2/M checkpoint and to enter into mitosis in the presence of unrepaired DNA damage as judged by histone gH2AX monitoring. Similar observation has been reported in human sarcoma cells in response to ionizing radiation 
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C Didier et al and characterized as checkpoint adaptation (Syljuasen et al., 2006) . Checkpoint adaptation may allow cells with excessive DNA damage to progress through mitosis, thus increasing the risk of genetic instability. We next show that the ability of the mature U937 and immature KG1a cells to enter mitosis could be abolished by the use of chemical inhibitors of CDC25 phosphatases. To further confirm the specific role of CDC25B in checkpoint recovery, we examined the consequence of its partial invalidation with RNA interference in mature U937 cells treated with the genotoxic agent VP-16. We demonstrate that in leukemia cells, as shown in other cell types Bugler et al., 2006) , the activity of the CDC25B is required for the re-entry into the cell cycle after a DNA-damage induced arrest. Consistent with other reports, these results fit nicely into a model in which CDC25B, in concert with PLK1, acts to restart the cell cycle after DNA damage Bugler et al., 2006) . Our observations suggest that an increase in CDC25B expression level is required to drive cells into mitosis following DNA-damage induced arrest. This result is in agreement with recent findings from Lazo's group demonstrating that CDC25B expression is upregulated in a p53-independent manner in a large panel of human tumor cell lines (Bansal and Lazo, 2007) . We have also found that the increase in CDC25B level is posttranscriptional as messenger ribonucleic acid level does not change after VP16 treatment in any of the tested cell lines (data not shown). However, it appears that CDC25B increase is not sufficient in KG1a cells to promote entry into mitosis, suggesting that an additional level of regulation is counteracting its mitosisinducing effect. We could eliminate a lack of PLK1 activity in KG1a (that is required for the degradation of the inhibitory WEE1 kinase by the proteasome) as we have found that in both U937 and KG1a cells, the use of a PLK1 inhibitor impaired entry into mitosis after VP-16 treatment (data not shown). We therefore examined the alternative possibility that in KG1a cells, CDC25B activity could be strongly inhibited by the CHK1 kinase pathway, thus restraining its mitotic inducing activity despite the elevation of its protein level.
We found that phosphorylation of CHK1 kinase was more persistant in immature KG1a than in mature U937, suggesting that the resistance of KG1a to genotoxic agents might be related to tighter checkpoint activation. This was further extended by the analyses of claspin levels in U937 and KG1a cells. Recently, it has been shown that full activation of CHK1 by ATR requires Claspin, which may act as a scaffolding protein that brings together ATR and CHK1 (Kumagai et al., 2004) . We found a tight correlation between the expression levels of claspin and CHK1 activation in both mature and immature leukemia cells. Our observations showed that PLK1 expression was not sufficient in KG1a cells to shift the balance back to the cell cycle.
A key issue that needs to be address is how immature AML cells regulate the duration of the G2/M checkpoint. Previous studies have shown that basal level of claspin is positively controlled by the CHK1 kinase activity Mamely et al., 2006) . This observation suggest the existence of a positive feedback loop, in which CHK1 acts to stabilize claspin, which in turn facilitates further activation of CHK1. We may postulate that in immature AML cells this feedback loop is overactivated. Further investigation will be required to test this hypothesis.
Furthermore, our findings indicate that in immature human leukemia KG1a cells, the CHK1 kinase inhibitor UCN-01 that functions as a checkpoint abrogator, potentiates the lethal effects of the DNA-damaging agent, VP-16. These results indicate that CHK1 is likely Chk1 and total Chk1 in AML patients blasts. Equal amounts of protein lysates from AML blasts were subjected to immunoblot analyses with the indicated antibodies. Actin was used as loading control. AML, acute myeloid leukemia; CHK1; checkpoint kinase 1; FAB, French-AmericanBritish; SF, sensitization factor. G2/M Checkpoint in AML C Didier et al to play a key role in the G2/M checkpoint activation of AML cells, probably through the phosphorylation and the inhibition of CDC25 phosphatases. It is also therefore very likely, as schematically illustrated in Figure 6 , that a robust activation of the ATR/claspin/ CHK1 pathway (Bartek and Lukas, 2007) , which leads to CDC25B phosphorylation and inactivation, is acting in KG1a cells thus rendering their checkpoint response extremely efficient and decreasing the efficiency of genotoxic treatment.
Finally, we examined whether the checkpoint abrogating effect of UCN-01 could sensitize primary leukemic cells from AML patients to genotoxic stress. We have found that the colony formation efficiency of primary leukemic cells from AML patients M1 and M2 (French-American-British classification (FAB)) exposed to UCN-01 in combination with VP-16, was strongly inhibited compared to the M4 and M5 groups. However, we could not detect any correlated variation in CHK1 level or activity to explain these results at the molecular level. Further studies will be required to investigate and compare in more detail the DNA-damage checkpoint response pathway between these two groups of patients.
Our observations, together with a recent report showing loss of cloning potential when blasts from patients where exposed to Ara-C in combination with UCN-01 (Sampath et al., 2006) , further reinforces a model in which a very active checkpoint pathway might be a common characteristic of immature leukemic cells.
Checkpoint abrogation can potentiate the efficacy of DNA damaging agents in cancer cells, and is therefore thought to represent an attractive therapeutic target for cancer treatment. The relevance of this strategy is further reinforced by the increasing experimental evidence for a G2/M checkpoint reinforcement in cancer stem cells, associated with increased CHK activity (Bao et al., 2006) .
Our findings suggest that combined treatment with UCN-01 and DNA damaging agents may warrant further examination as a novel therapeutic strategy in the treatment of AML. Further studies with blasts from a larger set of AML patients will be required to investigate and evaluate in detail the therapeutic potential for checkpoint inhibitors.
Materials and methods
Cell cultures U937 and KG1a were cultured as described (Fernandez-Vidal et al., 2006) . Leukemic blasts from patients were obtained upon informed consent from bone marrow aspirates by ficollHypaque density gradient centrifugation. Frozen cells were thawed in EGM2 medium (Fernandez-Vidal et al., 2006) supplemented with stem cell factor (100 ng ml À1 ), IL-3 (5 ng ml À1 ), Flt3 ligand (100 ng ml À1 ), and GM-CSF (10 ng ml À1 ). Cells were left at 1 Â 10 6 ml
À1
for 48 h in these conditions during which moderate cell death occurred (10-40% of the cells depending of the patient) then further processed.
Cytokines, pharmacologic inhibitors and reagents VP-16 was from Sigma (St Louis, MO, USA). UCN-01 was provided by the National Cancer Institute (Rockville, MD, USA). BN82685 was provided by the Institut Henri Beaufour (IPSEN). SCF, interleukin (IL)-3, Flt3 ligand (FL), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were from R&D Systems (Minneapolis, MN). Other products were purchased from Sigma (Saint Quentin-Fallavier, France).
Transfection of small interfering RNA 2 Â 10 6 cells were resuspended in 100 ml Nucleofector Kit V for U937 and kit L for KG1a according to manufacturer's instructions (Amaxa, Cologne, Germany). CDC25B siRNA (Kramer et al., 2004; Lindqvist et al., 2004) , CHK1 siRNA (Schmitt et al., 2006) or control siRNA (Eurogentec, Belgium) together with pRNATH1.1 green fluorescent protein expressing vector (Genescript) (Bugler et al., 2006) were added and cells were immediately transfected using the Amaxa nucleofector device (program V-001). Cells were subsequently resuspended in warm medium, cultured at 10 6 cells/ml and processed after 24 h for experiments.
Analysis of cell cycle progression, apoptosis and gH2AX staining Cells were harvested and fixed in ice-cold 70% ethanol. Cells were permeabilized with PBS-0.25% Triton X-100 and subsequently stained with rabbit anti-phospho-histone H3 (Upstate Biotechnology, Lake Placid, NY, USA) and propidium iodide. To select the transfected (green fluorescent protein-positive) cells, a paraformaldehyde fixation was Working model. Checkpoint recovery and entry into mitosis is dependent on the activity of the CDC25B phosphatase and on the PLK1 kinase that trigger proteasome-dependent degradation of the inhibitory WEE1 kinase and the adaptor protein, claspin. We propose that the reinforcement of the checkpoint in KG1a cells is linked to the strong inhibitory action of the CHK1 pathway on CDC25B. As demonstrated in this manuscript, inhibition of CDC25B (by BN82685 or siRNA) further inhibits entry into mitosis, while pharmacological inhibition of CHK1 by UCN-01 abrogates the checkpoint and favors illegitimate entry into mitosis. (See Discussion for further details). CHK1; checkpoint kinase 1; siRNA, small interfering RNA performed with the intrastain kit from DakoCytomation, and then the staining was performed as above. Data were collected on a BD FACSCalibur cytometer and analyzed using the Cell Quest (Becton Dickinson, Franklin Lakes, NJ, USA) and Modfit software (Verity Software). Apoptotic cells were detected with Annexin V-FITC detection kit from BD PharMingen (San Diego, CA, USA). Staining for gH2AX was conducted as described by the manufacturer (Euromedex/ Upstate Biotechnology; mouse monoclonal anti-phosphohistone gH2AX antibody; 1:500 dilution). DNA content for blast cells was processed using a coulter DNA Prep reagent kit (Beckman Coulter, Fullerton, CA, USA).
Colony formation analysis with AML patient cells Colony formation efficiency of primary leukemic cells were obtained from bone marrow aspirates from AML patients at diagnosis. Colony formation efficiency of primary leukemic cells were resuspended in H441000 methyl-cellulose medium complemented with 10% 5637-conditioned medium. UCN-01, VP-16 or DMSO was added at the indicated concentration, and the cells were incubated at 37 1C for 7 days. Colonies with more than 20 cells were scored.
Western blot analyses
Cells were harvested and lysed as described previously (Dutertre et al., 2004) . Protein Samples were separated on 4-12% bis-tris-gels, transferred onto nitrocellulose membrane, and immmunostained. Antibodies were: anti-CDC25B (1:1000) Santa Cruz Biotechnology (Santa Cruz, CA, USA), antipSer 345 CHK1 and anti-pSer 317 CHK1 (1:1000) Cell Signaling Technology (Beverly, MA, USA), anti-CHK1 (1:1000) from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-PLK1 (1:1000) from Zymed laboratories, anti-Wee1 (1:1000) Cell Signaling Technology (Beverly, MA, USA) and anti-actin (1:10 000) from Chemicon (Temecula, CA, USA).
Statistics
Results are expressed as mean values±standard deviations or standard error of the mean as indicated. Statistical analyses of the data were performed by unpaired student t-test. Differences were considered as significant for P-values less than 0.05.
